Alto Secures $120M in Institutional-Led Financing
On March 16, 2026, Alto Neuroscience announced it raised approximately $120 million in gross proceeds through a private placement financing. The deal, led by Commodore Capital, drew participation from a syndicate of new and existing biotech-focused institutional investors, including Dellora Investments and Perceptive Advisors. The transaction is structured with the sale of 2.9 million shares of common stock at $20.00 per share and 3.1 million pre-funded warrants at a price of $19.9999 per warrant. This capital injection, expected to close on March 17, 2026, demonstrates robust investor confidence in Alto's development strategy.
Financing Extends Runway to $275M for Phase 3 Depression Trial
The proceeds from the financing are earmarked to advance ALTO-207, the company's candidate for treatment-resistant depression (TRD), through a pivotal Phase 3 study. Alto plans to initiate a Phase 2b study of ALTO-207 in the first half of 2026, followed by the Phase 3 trial in early 2027. This new capital increases Alto's estimated cash and cash equivalents to approximately $275 million, providing a clear financial runway to complete the late-stage trial and, if successful, support a New Drug Application (NDA) submission. The funding solidifies the company's ability to pursue a key unmet need in psychiatric medicine.
This financing is expected to provide the resources needed to advance ALTO-207 through a Phase 3 study, a major step toward realizing the potential of this program.
— Amit Etkin, M.D., Ph.D., founder and chief executive officer of Alto Neuroscience.
